Tests for detection of ROS1 gene alterations in patients with non-small cell lung cancer - Protocol for a rapid review
The NIPH will evaluate genomic tests relevant for the identification of somatic ROS1 gene alterations in patients with locally advanced or metastatic non-small cell lung cancer.
About the project
-
Project period: 23.09.2020 - 15.02.2021 (Concluded)
- Coordinating Institution: Norwegian Institute of Public Health
-
Project Manager:
- Gerd Monika Flodgren, Norwegian Institute of Public Health
-
Project Participants:
- Vida Hamidi, Norwegian Institute of Public Health
- Elisabet Vivianne Hafstad, Norwegian Institute of Public Health
- Project plan: ROS1 projectplan.pdf
Summary
The Institute of Public Health has been commissioned to evaluate genomic tests relevant for the identification of somatic ROS1 gene alterations in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The Norwegian Medicines Agency (NoMA) will evaluate the treatment effect and safety of the drug Entrectinib (Rozlytrek) in the same population.